The HIV/HBV/HCV Test Kits Market is expected to be worth US$ 6,568.3 million in 2023, rising to US$ 11,573.9 million by 2033. During the forecast period, sales of HIV/HBV/HCV test kits are expected to grow at a significant CAGR of 5.8%.
The global incidence of HIV and hepatitis has increased significantly, and this is expected to drive HIV/HBV/HCV test kit consumption. With HIV and hepatitis infections being major public health issues around the world, there is a high demand for effective diagnostic services for these diseases.
- According to the WHO’s June 2022 report, an estimated 58 million people worldwide have chronic hepatitis C virus infection, with approximately 1.5 million new cases occurring each year. An estimated 3.2 million adolescents and children are infected with chronic hepatitis C. The disease’s high prevalence is expected to drive market growth.
Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9814
Governments and non-governmental organizations (NGOs) all over the world are taking steps to raise awareness about STD testing and its significance in the fight against HIV and hepatitis.
- This has resulted in a significant increase in global awareness, with initiatives such as ‘Start Talking. Stop HIV/AIDS’ and “World Hepatitis Day” every year to increase awareness and understanding of these chronic diseases.
Since early diagnosis improves disease treatment, these awareness campaigns are expected to increase demand for HIV/HBV/HCV test kits globally and accelerate market growth.
Rising medical diagnostics research and development, rising HIV and hepatitis incidence, increased awareness among the general population, increasing medical expenditure, technological developments in diagnostics, and other major factors are expected to drive consumption of HIV/HBV/HCV test kits.
Key Takeaways from the HIV/HBV/HCV Test Kits Market
- The North America HIV/HBV/HCV test kits market accounts for a dominant market position in the global marketplace, with a share of 33.4% in 2022, and is expected to maintain this position throughout the forecast period. Rising cases of sexually transmitted infections (STIs) and sexually transmitted diseases (STDs) in the region are responsible for HIV/HBV/HCV test kit sales significantly.
Contact our Market Research Specialist: https://www.futuremarketinsights.com/ask-question/rep-gb-9814
- The blood sample segment is anticipated to witness strong growth of 6.1% during the 2023-2033 period. The primary reason for the expansion of this segment is the increased number of tests required prior to blood or blood product transfusion. The increasing use of serological tests for blood group typing, as well as mandatory screening tests for HIV, HCV, HBV, syphilis, and malaria, are driving the segment’s growth.
- East Asian and South Asian markets for HIV/HBV/HCV testing equipment currently account for 21.9% and 6.2% of the global industry, respectively. Sales of HIV/HBV/HCV test kits in these regions are projected to be fueled by densely populated nations such as India and China as their emphasis on healthcare grows.
- The market’s primary part, assay-based test kits, is growing at a 6.4% annual pace. Assay kits are the primary method used for patient testing. Moreover, assay-based testing findings are used by medical professionals and patients in the majority of developing nations.
Manufacturers are constantly evolving business models
Companies in the HIV/HBV/HCV test kits market are moderately competitive by nature, with several major players present. These players are part of several strategic alliances. The agreement and system automation speed up the manufacturer’s strategy to capitalize on market share and capture a sizable market share.
Browse the Full Report with Facts and Figures of HIV/HBV/HCV Test Kits Market Report at: https://www.futuremarketinsights.com/checkout/9814
Key Companies Profiled:
BioMerieux SA, Bio-Rad Laboratories Inc, Diasorin S.p.A, F. Hoffmann-La Roche AG, Hologic Inc, MedMira Inc, Qaigen Inc, Grifols SA, Sysmex Corporation, and Siemens Healthineers
Latest Developments
- November 2021 – Siemens Healthineers AG and Hemogenomics funded a clinical trial to compare the ADVIA Centaur XP chemiluminescence system for HIV, HCV, and Syphilis screening in blood donors from India.
- NATSpert, an Individual Donor Nucleic Acid Test (ID-NAT) to screen for HIV, HBV, and HCV in donated blood, was launched in April 2019 by Mylab Discovery Solutions.
HIV/HBV/HCV Test Kits Market by Solution
HIV/HBV/HCV Test Kits Market by Test Kit Type:
- Assay-based Test Kits
- Rapid Test Kits
HIV/HBV/HCV Test Kits Market by Sample:
- Blood
- Urine
- Saliva
HIV/HBV/HCV Test Kits Market by End User:
- HIV/HBV/HCV Test Kits for Hospitals
- HIV/HBV/HCV Test Kits for Clinics
- HIV/HBV/HCV Test Kits for Diagnostic Laboratories
- HIV/HBV/HCV Test Kits for Government Organizations and NGOs
- Others
Explore FMI’s Extensive Ongoing Coverage in Healthcare Domain:
- https://masterpaper.mn.co/posts/34176384
- https://fadaako.mn.co/posts/34176386
- https://ledpanellights.mn.co/posts/34176387
About Future Market Insights (FMI)
Future Market Insights (ESOMAR-certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel, and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs